营养补充剂与植物制剂治疗精神分裂症:系统综述与网络Meta分析「Nutra NMA SCZ」
该系统综述与网络Meta分析纳入50项随机对照试验(n=2384)、22种干预,评估营养补充剂/植物制剂对精神分裂症或分裂情感障碍的增效治疗。胞磷胆碱、L-赖氨酸、N-乙酰半胱氨酸和肌氨酸在总症状上优于安慰剂增效治疗,但证据质量低至极低;急性期研究未见任何化合物改善总症状。
要点
- 在临床稳定患者中,肌氨酸、胞磷胆碱和N-乙酰半胱氨酸优于安慰剂增效治疗。
- 急性期研究(k=7,n=422)中未见任何化合物改善总症状。
- 因任何原因或不良事件导致的脱落率在营养补充剂/植物制剂与安慰剂+常规治疗之间无差异。
核心结论
- 肌氨酸、胞磷胆碱和N-乙酰半胱氨酸是精神分裂症稳定期患者有前景的增效干预措施,但证据质量低至极低。
- 需要在急性期/特定结局/难治性精神分裂症中开展进一步高质量试验。
研究设计与样本
- 系统综述与网络Meta分析,纳入49条记录共50项随机对照试验(n=2384),涵盖22种干预。
- 检索数据库包括PubMed、MEDLINE、EMBASE、Scopus、PsycINFO、CENTRAL和ClinicalTrials.gov。
- 共同主要结局为总症状严重程度变化(标准化均数差SMD)和可接受性(风险比RR)。
主要发现
- 胞磷胆碱(SMD=-1.05,95%CI -1.85至-0.24)、L-赖氨酸(SMD=-1.04,95%CI -1.84至-0.25)、N-乙酰半胱氨酸(SMD=-0.87,95%CI -1.27至-0.47)和肌氨酸(SMD=-0.5,95%CI -0.87至-0.13)在总症状上优于安慰剂。
- 肌氨酸改善阴性症状(SMD=-0.65,95%CI -1.10至-0.19);N-乙酰半胱氨酸改善阴性症状(SMD=-0.90,95%CI -1.42至-0.39)和一般精神病理(SMD=-0.76,95%CI -1.39至-0.13)。
- 急性期研究(k=7,n=422)中无任何化合物改善总症状。
- 在临床稳定参与者中,肌氨酸(SMD=-1.26,95%CI -1.91至-0.60)、胞磷胆碱(SMD=-1.05,95%CI -1.65至-0.44)和N-乙酰半胱氨酸(SMD=-0.55,95%CI -0.92至-0.19)优于安慰剂增效治疗。
- 去除高偏倚风险研究的敏感性分析证实所有阶段和临床稳定样本的总体发现;限制于低偏倚风险研究的急性期分析显示N-乙酰半胱氨酸(SMD=-1.10,95%CI -1.75至-0.45)、L-赖氨酸(SMD=-1.05,95%CI -1.55至-0.19)、omega-3脂肪酸(SMD=-0.83,95%CI -1.31至-0.34)和南非醉茄(Withania somnifera,SMD=-0.71,95%CI -1.21至-0.22)优于安慰剂。
关键数值与推荐
- 总症状异质性tau²=0.10,I²=55.9%;全局不一致性Q=40.79,df=18,p=0.002;Egger检验p=0.42未提示发表偏倚。
- 因任何原因或不良事件导致的脱落率在营养补充剂/植物制剂与安慰剂+常规治疗之间无差异。
- 证据质量低至极低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 高异质性(tau²=0.10,I²=55.9%)和全局不一致性(Q=40.79,df=18,p=0.002)。
- 证据质量低至极低。
- 需要在急性期/特定结局/难治性精神分裂症中开展进一步高质量试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sub-optimal response in schizophrenia is frequent, warranting augmentation strategies over treatment-as-usual (TAU). We assessed nutraceuticals/phytoceutical augmentation strategies via network meta-analysis. Randomized controlled trials in schizophrenia/schizoaffective disorder were identified via the following databases: PubMed, MEDLINE, EMBASE, Scopus, PsycINFO, CENTRAL, and ClinicalTrials.gov. Change (Standardized Mean Difference = SMD) in total symptomatology and acceptability (Risk Ratio = RR) were co-primary outcomes. Secondary outcomes were positive, negative, cognitive, and depressive symptom changes, general psychopathology, tolerability, and response rates. We conducted subset analyses by disease phase and sensitivity analyses by risk of bias and assessed global/local inconsistency, publication bias, risk of bias, and confidence in the evidence. The systematic review included 49 records documenting 50 studies (n = 2384) documenting 22 interventions. Citicoline (SMD =-1.05,95%CI = -1.85; -0.24), L-lysine (SMD = -1.04,95%CI = -1.84; -0.25), N-acetylcysteine (SMD = -0.87, 95%CI = -1.27; -0.47) and sarcosine (SMD = -0.5,95%CI = -0.87-0.13) outperformed placebo for total symptomatology. High heterogeneity (tau2 = 0.10, I2 = 55.9%) and global inconsistency (Q = 40.79, df = 18, p = 0.002) emerged without publication bias (Egger's test, p = 0.42). Sarcosine improved negative symptoms (SMD = -0.65, 95%CI = -1.10; -0.19). N-acetylcysteine improved negative symptoms (SMD = -0.90, 95%CI = -1.42; -0.39)/general psychopathology (SMD = -0.76, 95%CI = -1.39; -0.13). No compound improved total symptomatology within acute phase studies (k = 7, n = 422). Sarcosine (SMD = -1.26,95%CI = -1.91; -0.60), citicoline (SMD = -1.05,95%CI = -1.65;-0.44), and N-acetylcysteine (SMD = -0.55,95%CI = -0.92,-0.19) outperformed placebo augmentation in clinically stable participants. Sensitivity analyses removing high-risk-of-bias studies confirmed overall findings in all phases and clinically stable samples. In contrast, the acute phase analysis restricted to low risk-of-bias studies showed a superior effect vs. placebo for N-acetylcysteine (SMD = -1.10, 95%CI = -1.75,-0.45), L-lysine (SMD = -1.05,95%CI = -1.55, -0.19), omega-3 fatty acids (SMD = -0.83,95%CI = -1.31, -0.34) and withania somnifera (SMD = -0.71,95%CI = -1.21,-0.22). Citicoline (SMD = -1.05,95%CI = -1.86,-0.23), L-lysine (SMD = -1.04,95%CI = -1.84,-0.24), N-acetylcysteine (SMD = -0.89,95%CI = -1.35,-0.43) and sarcosine (SMD = -0.61,95%CI = -1.02,-0.21) outperformed placebo augmentation of TAU ("any phase"). Drop-out due to any cause or adverse events did not differ between nutraceutical/phytoceutical vs. placebo+TAU. Sarcosine, citicoline, and N-acetylcysteine are promising augmentation interventions in stable patients with schizophrenia, yet the quality of evidence is low to very low. Further high-quality trials in acute phases/specific outcomes/difficult-to-treat schizophrenia are warranted.
引用
- Fornaro M, Caiazza C, Billeci M, et al. Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis "Nutra NMA SCZ". Mol Psychiatry. 2024. PMID: 39026098. doi:10.1038/s41380-024-02645-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。